Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Cyprus

European Research Council grant · Finished

LiveBioThx Live biotherapeutics to potentiate cancer immunotherapy

Coordinator
University of Cyprus, Cyprus
Runs
1 March 2023 to 31 August 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101100769

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy, including immune checkpoint inhibitors (ICIs), has revolutionized the treatment of multiple cancers. Anti-tumor responses are often durable but overall only a subset of patients receiving ICIs has exhibited sustained tumor shrinkage, whereas a substantial fraction receiving these therapies develops immune-related adverse events. The absence of dramatic responses is attributed to several factors, including abnormalities in the tumor microenvironment (TME).

Specifically, many tumors such as subsets of colorectal, breast and pancreatic cancer, become stiff as they grow. Tumor stiffening causes compression of intratumor blood vessels, impairing blood flow/perfusion and oxygen supply. Hypoperfusion reduces ICIs delivery to the tumor and hypoxia induces immunosuppression, compromising immunotherapy. To restore these abnormalities, a novel therapeutic strategy to normalize tumor stiffness prior to ICIs has been tested in preclinical studies and in the clinic.

This strategy repurposes clinically approved drugs to target the factors contributing to tumor stiffening, leading to a new class of therapeutics, known as mechanotherapeutics. However, drug-repurposing poses certain limitations as adding a new drug to the treatment regimen of patients with cancer is not feasible in many cases. As an alternative to these approaches, we propose here to test the ability of engineered live biotherapeutics in the form of programmable bacteria that offer unique advantages for delivering enzymes to normalize the TME.

Even a small fraction of bacterial dose reaching the tumor is sufficient to colonize it and allow therapeutic concentrations of tumor-remodeling enzymes to be maintained for a long period of time. We propose to evaluate the ability of a novel live biotherapeutic product to improve perfusion and potentiate ICIs in preclinical tumor models of colorectal and breast tumors. This bacterial product has great potential for commercialization, and a plan is proposed.

Topics

Who is involved

OrganisationCityCountryRole
University of CyprusNicosiaCyprusCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI